Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7335-7342

  Dhawan, Punita ^a   Singh, Amar B ^a   Ellis, Darrel L ^a   Richmond, Ann ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; PROTEIN P50; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; GENE ACTIVATION; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOMA; NEVUS; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL SURVIVAL; DISEASE PROGRESSION; ENZYME ACTIVATION; HUMANS; I-KAPPA B KINASE; MELANOMA; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0037115394     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Ries, L. A. G., Wingo. P. A., Miller, D. S., Howe, H. L., Weir, H. K., Rosenberg, H. M., Vernon. S. W., Cronin, K., and Edwards. B. K. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer (Phila.), 88: 2398-2424, 2000.
2. Rigel, D. S., Friedman, R. J., and Kopf, A. W. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J. Am. Acad. Dermatol., 34: 839-847, 1996.
3. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 47: 5-27, 1997.
4. Schneider, G. P., Salcedo, R., Welniak, L. A., Howard, O. M., and Murphy, W. J. The diverse role of chemokines in tumor progression: Prospects for intervention. Int. J. Mol. Med., 8: 235-244, 2001.
5. Rhodes, A. R. Benign neoplasias and hyperplasias of melanocytes. Dysplastic melanocytic nevi. In: I. M. Freedberg, A. Z. Eisen, K. Wolff, K. F. Austen, L. A. Goldsmith, S. I. Katz, and T. B. Fitzpatrick (eds.), Dermatology in General Medicine. pp. 1018-1059 and 1060-1079. New York: McGraw-Hill, 1999.
6. Langley, R. G. B., Barnhill R. L., Mihm, M. C., Jr., Fitzpatrick, T. B., and Sober, A. J. Neoplasms: Cutaneous melanoma, In: I. M. Freedberg, A. Z. Eisen, K. Wolff, K. F. Austen, L. A. Goldsmith, S. I. Katz, and T. B. Fitzpatrick (eds.), Dermatology in General Medicine, pp. 1080-1116. New York: McGraw-Hill, 1999.
7. Schneider, J. S., Moore, D. H., and Sagebiel. R. W. Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) nevi. Arch. Dermatol., 130: 1002-1007, 1994.
8. st century. CA Cancer J. Clin., 50: 215-236, 2000.
9. Duncan, L. M., Berwick. M., Bruijn, J. A., Byers, H. R., Mihm, M. C., and Barnhill, R. L. Histopathologic recognition and grading of dysplastic melanocytic nevi: An interobserver agreement study, J. Investig. Dermatol., 100: 318S-321S, 1993.
10. Duray. P. H., DerSimonian, R., Barnhill, R., Stenn, K., Ernstoff, M. S., Fine. J., and Kirkwood, J. M. An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J. Am. Acad. Dermatol., 27: 741-749, 1992.
11. Ahmed, I., Piepkorn, M., Goldgar, D. E., Cannon-Albright, L. A., Meyer, L. J., Skolnick, M. H., and Zone, J. J. HMB-45 staining of dysplastic melanocytic nevi in melanoma risk groups. J. Cutan. Pathol., 18: 257-260, 1991.
12. Ruiter, D. J., Spatz, A., van den Oord. J. J., and Cook. M. G. Microstaging in cutaneous melanoma. J. Pathol., 195: 525-529, 2001.
13. Sharma, H. W., and Narayanan, R. The NF-κB transcription factor in oncogenesis. Anticancer Res., 16: 589-596, 1996.
14. Luque, I., and Gélinas. C. Rel/NF-κB, and IκB factors in oncogenesis. Semin. Cancer Biol., 8: 103-111, 1997.
15. Gilmore, T, D., Koedood, M., Piffat, K. A., and White, D. W. Rel/NF-κB/IκB proteins and cancer. Oncogene, 13: 1367-1378, 1996.
16. Bargou. R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dorken. B. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Investig., 100: 2961-2969, 1997.
17. Sunwoo, J. B., Chen. Z., Dong, G., Yeh, N., Crowl Bancroft. C., Sausville, E., Adams, J., Elliott, P., and Van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res., 7: 1419-1428, 2001.
18. Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski. G. J., Rogers, A. E., Traish. A. M., and Sonenshein, G. E. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Investig., 100: 2952-2960, 1997.
19. Shattack-Brandt, R. L., and Richmond, A. Enhanced degradation of IκBα contributes to endogenous activation of NF-κB in Hs294T melanoma cells. Cancer Res., 57: 3032-3039, 1997.
20. Karin, M. How NF-κB is activated: The role of the IκB kinase (IKK) complex. Oncogene, 18: 6867-6874, 1999.
21. Woronicz, J. D., Gao, X., Cao, Z., Rothe, M., and Goeddel, D. V. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science (Wash. DC), 278: 866-869, 1997.
22. Israel. A. The IKK complex: An integrator of all signals that activate NF-κB? Trends Cell. Biol., 10: 129-133, 2000.
23. Li, X. H., Fang, X., and Gaynor, R. B. Role of IKKγ/nemo in assembly of the IκB kinase complex. J. Biol, Chem., 276: 4494-4500, 2001.
24. Harlan, J. E., Yoon, H. S., Hajduk, P. J., and Fesik, S. W, Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate, Biochemistry, 34: 9859-9864, 1995.
25. Karin, M., and Lin, A. NF-κB at the crossroads of life and death. Nat. Immunol., 3: 221-227. 2002.
26. Datta, S. R., Dudek. H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, Cell, 91: 231-241, 1997.
27. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science (Wash. DC), 282: 1318-1321, 1998.
28. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868, 1999.
29. Romashkova, J. A., and Makarov, S. S. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature (Lond.), 401: 86-90, 1999.
30. Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altemare, D. A., Wan, M., Dubeau. L., Scambia, G., Masciullo, V., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer. 64: 280-285, 1995.
31. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare. D. A., Watson. D. K., and Testa, J. R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci, USA, 93: 3636-3641, 1996.
32. Cheng, J. Q., Godwin. A. K., Bellacosa. A., Taguchi, T., Franke. T. F., Hamilton, T. C., Tsichlis, P. N., and Testa, J. R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad Sci. USA, 89: 9267-9271, 1992.
33. Yuan, Z. Q., Sun, M., Feldman. R. I., Wang, G., Ma, X., Jiang, C., Coppola, D., Nicosia, S. V., and Cheng, J. Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer, Oncogene. 19: 2324-2330, 2000.
34. Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z. Q., Ma, X. L., Shelley, S. A., Jove. R., Tsichlis, P. N., Nicosia, S. V., and Cheng, J. Q. AKTI/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol., 159: 431-437, 2001.
35. Haas-Kogan, D., Shaiev. N., Wong, M., Mills. G., Yount, G., and Stokoe, D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol., 8: 1195-1198, 1998.
36. Dahia, P. L., Aguiar, R. C., Alberta, J., Kum, J. B., Caron, S., Sill, H., Marsh, D. J., Ritz, J., Freedman, A., Stiles, C., and Eng, C. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum. Mol. Genet., 8: 185-193, 1999.
37. Dhawan, P., and Richmond, A. A novel NF-κB-inducing kinase-MAPK signaling pathway up-regulates NF-κB activity in melanoma cells. J. Biol. Chem., 277: 7920-7928, 2002.
38. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma (January 27-29, 1992). Am. J. Dermatopathol. 15: 34-43, 1993.
39. Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., and Hemmings, B. A. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem., 272: 31515-31524, 1997.
40. Camper-Kirby, D., Welch, S., Walker, A., Shiraishi, I., Setchell, K. D., Schaefer, E., Kajstura, J., Anversa, P., and Sussman. M. A. Myocardial Akt activation and gender: Increased nuclear activity in females versus males. Circ. Res., 25: 1020-1027, 2001.
41. Tsatsanis. C., and Spandidos, D. A. The role of oncogenic kinases in human cancer. Int. J. Mol. Med., 5: 583-590, 2000.
42. Farmer, E. R., and Hood, A. F. Melanocytic tumors. In: E. R. Farm A. F. Hood (eds.) Pathology of the Skin, 2nd Ed., pp. 1105-1155. New York: McGraw-Hill, 2000.
43. Sonoda, Y., Ozawa, T., Aldape, K. D., Deen, D. F., Berger, M. S., and Pieper, R. O. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res., 61: 6674-6678, 2001.
44. Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., and Muller, W. J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol. Cell, Biol., 21: 2203-2212, 2001.
45. Tachiiri, S., Sasai, K., Oya, N., and Hiraoka, M. Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Ap85, following genetoxic stresses. Jpn. J. Cancer Res., 91: 1314-1318, 2001.
46. Li, G., Satyamoorthy, K., and Herlyn, M. N-Cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res., 61: 3819-3825, 2001.
47. Madrid, L. V., Wang, C. Y., Guttridge, D. C., Schottelius, A. J., Baldwin. A. S., Jr., and Mayo, M. W. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol. Cell. Biol., 20: 1626-1638, 2000.
48. Alessi, D. R., Caudwell, F. B., Andjelkovic, M., Hemmings, B. A., and Cohen, P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett., 399: 333-338. 1996b.
49. Waldmann, V., Wacker, J., and Deichmann. M. Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. Melanoma Res., 12: 45-50, 2002.
50. Waldmann, V., Wacker, J., and Deichmann. M. Mutations of the activation-associated phosphorylation sites at codons 308 and 473 of protein kinase B are absent in human melanoma. Arch. Dermatol. Res., 293: 368-372, 2001.